Zacks Research Expects Reduced Earnings for Globus Medical

Globus Medical, Inc. (NYSE:GMED) – Investment analysts at Zacks Research dropped their Q1 2025 earnings estimates for Globus Medical in a report released on Thursday, March 13th. Zacks Research analyst R. Department now forecasts that the medical device company will post earnings of $0.73 per share for the quarter, down from their prior forecast of $0.79. The consensus estimate for Globus Medical’s current full-year earnings is $3.44 per share. Zacks Research also issued estimates for Globus Medical’s Q3 2025 earnings at $0.87 EPS, Q4 2025 earnings at $0.97 EPS, Q1 2026 earnings at $0.87 EPS, Q2 2026 earnings at $0.92 EPS, Q3 2026 earnings at $0.99 EPS, Q4 2026 earnings at $1.14 EPS and FY2027 earnings at $4.49 EPS.

Several other equities research analysts have also recently issued reports on the stock. Needham & Company LLC reissued a “hold” rating on shares of Globus Medical in a research report on Tuesday. Truist Financial decreased their target price on shares of Globus Medical from $90.00 to $82.00 and set a “hold” rating on the stock in a research report on Tuesday. Barclays lifted their price target on shares of Globus Medical from $100.00 to $103.00 and gave the company an “overweight” rating in a research report on Monday, February 24th. Wells Fargo & Company reduced their price target on shares of Globus Medical from $95.00 to $93.00 and set an “overweight” rating on the stock in a research report on Friday, February 21st. Finally, Stifel Nicolaus lifted their price target on shares of Globus Medical from $92.00 to $94.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Three research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $97.09.

Globus Medical Price Performance

Shares of NYSE GMED opened at $71.63 on Monday. The company has a 50-day simple moving average of $84.39 and a 200-day simple moving average of $79.79. Globus Medical has a 12 month low of $49.33 and a 12 month high of $94.93. The company has a market cap of $9.85 billion, a PE ratio of 95.50, a price-to-earnings-growth ratio of 1.61 and a beta of 1.19.

Globus Medical (NYSE:GMED) last issued its quarterly earnings results on Thursday, February 20th. The medical device company reported $0.84 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.10. The business had revenue of $657.29 million during the quarter, compared to the consensus estimate of $646.19 million. Globus Medical had a net margin of 4.09% and a return on equity of 10.83%.

Insider Transactions at Globus Medical

In related news, CFO Keith W. Pfeil sold 14,167 shares of Globus Medical stock in a transaction on Friday, January 10th. The shares were sold at an average price of $88.29, for a total value of $1,250,804.43. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 18.54% of the company’s stock.

Institutional Trading of Globus Medical

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Oak Thistle LLC bought a new stake in shares of Globus Medical in the fourth quarter worth $376,000. bLong Financial LLC bought a new stake in shares of Globus Medical in the fourth quarter worth $397,000. Kathmere Capital Management LLC bought a new stake in shares of Globus Medical in the fourth quarter worth $23,091,000. Quest Partners LLC bought a new stake in Globus Medical during the third quarter valued at $523,000. Finally, Intech Investment Management LLC increased its stake in Globus Medical by 291.3% during the third quarter. Intech Investment Management LLC now owns 20,530 shares of the medical device company’s stock valued at $1,469,000 after purchasing an additional 15,283 shares during the last quarter. Institutional investors own 95.16% of the company’s stock.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.